It’s been a year of anticipation for Lykos Therapeutics, as they await a landmark decision from the Food and Drug Administration (FDA). The drugmaker had filed an application to approve MDMA as a treatment for PTSD, expecting a positive outcome that would catapult them to new heights.
However, on August 9, the FDA responded with a rebuttal, culminating growing concerns about the quality of Lykos’ clinical trials. Following the decision, the journal Psychopharmacology retracted three studies related to MDMA research, citing unethical practices and making serious allegations, including sexual misconduct by an unlicensed therapist at one of the study sites. Many of the authors implicated in these retractions had ties to Lykos.
This development represents a significant setback for what was once heralded as a groundbreaking innovation in the field of psychedelic medicine. The FDA’s disapproval not only casts doubt on the immediate future of psychedelic therapies, but also underscores the need for a profound transformation within the research culture itself. For the field to recover and move forward, a fundamental shift will be needed that prioritizes ethical conduct and rigorous scientific standards above all else.